These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 21635254)

  • 1. Design of clinically useful macromolecular iron chelators.
    Zhou T; Winkelmann G; Dai ZY; Hider RC
    J Pharm Pharmacol; 2011 Jul; 63(7):893-903. PubMed ID: 21635254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Macromolecular Iron Chelators.
    Bulbake U; Singh A; Domb AJ; Khan W
    Curr Med Chem; 2019; 26(2):323-334. PubMed ID: 30182850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of iron chelators with therapeutic application.
    Zhou T; Ma Y; Kong X; Hider RC
    Dalton Trans; 2012 Jun; 41(21):6371-89. PubMed ID: 22391807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, iron binding and antimicrobial properties of hexadentate 3-hydroxypyridinones-terminated dendrimers.
    Zhou T; Chen K; Kong LM; Liu MS; Ma YM; Xie YY; Hider RC
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2504-2512. PubMed ID: 29886020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-Hydroxypyridinone derivatives as metal-sequestering agents for therapeutic use.
    Santos MA; Chaves S
    Future Med Chem; 2015; 7(3):383-410. PubMed ID: 25826364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chelating agents for the treatment of systemic iron overload.
    Ma Y; Zhou T; Kong X; Hider RC
    Curr Med Chem; 2012; 19(17):2816-27. PubMed ID: 22455586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and iron(III)-chelating properties of novel 3-hydroxypyridin-4-one hexadentate ligand-containing copolymers.
    Zhou T; Kong XL; Liu ZD; Liu DY; Hider RC
    Biomacromolecules; 2008 May; 9(5):1372-80. PubMed ID: 18373358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescent 3-hydroxy-4-pyridinone hexadentate iron chelators: intracellular distribution and the relevance to antimycobacterial properties.
    Nunes A; Podinovskaia M; Leite A; Gameiro P; Zhou T; Ma Y; Kong X; Schaible UE; Hider RC; Rangel M
    J Biol Inorg Chem; 2010 Aug; 15(6):861-77. PubMed ID: 20364296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron binding dendrimers: a novel approach for the treatment of haemochromatosis.
    Zhou T; Neubert H; Liu DY; Liu ZD; Ma YM; Kong XL; Luo W; Mark S; Hider RC
    J Med Chem; 2006 Jul; 49(14):4171-82. PubMed ID: 16821777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and physicochemical assessment of novel 2-substituted 3-hydroxypyridin-4-ones, novel iron chelators.
    Moridani MY; Tilbrook GS; Khodr HH; Hider RC
    J Pharm Pharmacol; 2002 Mar; 54(3):349-64. PubMed ID: 11902801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values.
    Liu ZD; Khodr HH; Liu DY; Lu SL; Hider RC
    J Med Chem; 1999 Nov; 42(23):4814-23. PubMed ID: 10579844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
    Kontoghiorghes GJ; Pattichis K; Neocleous K; Kolnagou A
    Curr Med Chem; 2004 Aug; 11(16):2161-83. PubMed ID: 15279556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral iron chelators--development and application.
    Liu DY; Liu ZD; Hider RC
    Best Pract Res Clin Haematol; 2002 Jun; 15(2):369-84. PubMed ID: 12401312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The design and properties of 3-hydroxypyridin-4-one iron chelators with high pFe(3+) values.
    Hider RC; Liu ZD; Piyamongkol S
    Transfus Sci; 2000 Dec; 23(3):201-9. PubMed ID: 11099896
    [No Abstract]   [Full Text] [Related]  

  • 15. The design of orally active iron chelators.
    Hider RC; Zhou T
    Ann N Y Acad Sci; 2005; 1054():141-54. PubMed ID: 16339660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acyclonucleoside iron chelators of 1-(2-hydroxyethoxy)methyl-2-alkyl-3-hydroxy-4-pyridinones: potential oral iron chelation therapeutics.
    Liu G; Men P; Kenner GH; Miller SC; Bruenger FW
    Nucleosides Nucleotides Nucleic Acids; 2004; 23(3):599-611. PubMed ID: 15113026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of clinically useful iron(III)-selective chelators.
    Liu ZD; Hider RC
    Med Res Rev; 2002 Jan; 22(1):26-64. PubMed ID: 11746175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical features of in use and in progress chelators for iron overload.
    Nurchi VM; Crisponi G; Lachowicz JI; Medici S; Peana M; Zoroddu MA
    J Trace Elem Med Biol; 2016 Dec; 38():10-18. PubMed ID: 27365273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhodamine labeling of 3-hydroxy-4-pyridinone iron chelators is an important contribution to target Mycobacterium avium infection.
    Moniz T; Nunes A; Silva AM; Queirós C; Ivanova G; Gomes MS; Rangel M
    J Inorg Biochem; 2013 Apr; 121():156-66. PubMed ID: 23384853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in iron chelation: an update.
    Heli H; Mirtorabi S; Karimian K
    Expert Opin Ther Pat; 2011 Jun; 21(6):819-56. PubMed ID: 21449664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.